These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
178 related items for PubMed ID: 16487832
1. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. Wessely R, Schömig A, Kastrati A. J Am Coll Cardiol; 2006 Feb 21; 47(4):708-14. PubMed ID: 16487832 [Abstract] [Full Text] [Related]
2. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Wessely R, Blaich B, Belaiba RS, Merl S, Görlach A, Kastrati A, Schömig A. Thromb Haemost; 2007 Jun 21; 97(6):1003-12. PubMed ID: 17549304 [Abstract] [Full Text] [Related]
3. Drug-eluting stents. García-García HM, Vaina S, Tsuchida K, Serruys PW. Arch Cardiol Mex; 2006 Jun 21; 76(3):297-319. PubMed ID: 17091802 [Abstract] [Full Text] [Related]
4. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). Fröbert O, Lagerqvist B, Carlsson J, Lindbäck J, Stenestrand U, James SK. J Am Coll Cardiol; 2009 May 05; 53(18):1660-7. PubMed ID: 19406341 [Abstract] [Full Text] [Related]
5. Technology Insight: an overview of research in drug-eluting stents. Ong AT, Serruys PW. Nat Clin Pract Cardiovasc Med; 2005 Dec 05; 2(12):647-58. PubMed ID: 16306921 [Abstract] [Full Text] [Related]
6. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J. Eur J Pharmacol; 2005 Nov 07; 524(1-3):19-29. PubMed ID: 16271360 [Abstract] [Full Text] [Related]
7. Polymer-based paclitaxel-eluting coronary stents. Clinical results in de novo lesions. Chieffo A, Colombo A. Herz; 2004 Mar 07; 29(2):147-51. PubMed ID: 15054587 [Abstract] [Full Text] [Related]
8. Cypher versus taxus: are there differences? Silber S. J Interv Cardiol; 2005 Dec 07; 18(6):441-6. PubMed ID: 16336424 [Abstract] [Full Text] [Related]
10. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents? Zhao FH, Chen YD, Jin ZN, Lu SZ. Med Hypotheses; 2008 Sep 07; 70(3):512-4. PubMed ID: 17764856 [Abstract] [Full Text] [Related]
11. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Muldowney JA, Stringham JR, Levy SE, Gleaves LA, Eren M, Piana RN, Vaughan DE. Arterioscler Thromb Vasc Biol; 2007 Feb 07; 27(2):400-6. PubMed ID: 17158352 [Abstract] [Full Text] [Related]
12. Experimental efficacy of an everolimus eluting cobalt chromium stent. Carter AJ, Brodeur A, Collingwood R, Ross S, Gibson L, Wang CA, Haller S, Coleman L, Virmani R. Catheter Cardiovasc Interv; 2006 Jul 07; 68(1):97-103. PubMed ID: 16755598 [Abstract] [Full Text] [Related]
13. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents. Iijima R, Mehilli J, Schömig A, Kastrati A. Minerva Cardioangiol; 2006 Oct 07; 54(5):539-55. PubMed ID: 17019392 [Abstract] [Full Text] [Related]
14. Endothelial cell recovery between comparator polymer-based drug-eluting stents. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. J Am Coll Cardiol; 2008 Jul 29; 52(5):333-42. PubMed ID: 18652940 [Abstract] [Full Text] [Related]
15. Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus. Giordano A. Curr Opin Drug Discov Devel; 2010 Mar 29; 13(2):159-68. PubMed ID: 20205050 [Abstract] [Full Text] [Related]
16. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. J Am Coll Cardiol; 2006 Jul 04; 48(1):193-202. PubMed ID: 16814667 [Abstract] [Full Text] [Related]
17. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. Clever YP, Cremers B, Krauss B, Böhm M, Speck U, Laufs U, Scheller B. EuroIntervention; 2011 May 04; 7 Suppl K():K32-42. PubMed ID: 22027725 [Abstract] [Full Text] [Related]
18. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati A. Eur Heart J; 2009 Apr 04; 30(8):923-31. PubMed ID: 19240066 [Abstract] [Full Text] [Related]
19. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent. Li JJ, Xu B, Yang YJ, Chen JL, Qiao SB, Ma WH, Qin XW, Yao M, Liu HB, Wu YJ, Yuan JQ, Chen J, You SJ, Dai J, Xia R, Gao RL. Chin Med J (Engl); 2007 Apr 05; 120(7):569-73. PubMed ID: 17442204 [Abstract] [Full Text] [Related]
20. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis. Silva GV, Fernandes MR, Madonna R, Clubb F, Oliveira E, Jimenez-Quevedo P, Branco R, Lopez J, Angeli FS, Sanz-Ruiz R, Vaughn WK, Zheng Y, Baimbridge F, Canales J, Cardoso CO, Assad JA, Falotico R, Perin EC. Catheter Cardiovasc Interv; 2009 May 01; 73(6):801-8. PubMed ID: 19309735 [Abstract] [Full Text] [Related] Page: [Next] [New Search]